- Home
- SABS vs NXTC Comparison
SABS vs NXTC Comparison
Compare SABS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- NXTC
- Stock Information
- Founded
- SABS 2014
- NXTC 2015
- Country
- SABS United States
- NXTC United States
- Employees
- SABS N/A
- NXTC N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- NXTC Health Care
- Exchange
- SABS Nasdaq
- NXTC Nasdaq
- Market Cap
- SABS 15.8M
- NXTC 13.9M
- IPO Year
- SABS N/A
- NXTC 2019
- Fundamental
- Price
- SABS $2.75
- NXTC $5.01
- Analyst Decision
- SABS Strong Buy
- NXTC Strong Buy
- Analyst Count
- SABS 5
- NXTC 3
- Target Price
- SABS $11.80
- NXTC $33.00
- AVG Volume (30 Days)
- SABS 37.3K
- NXTC 20.2K
- Earning Date
- SABS 08-07-2025
- NXTC 07-31-2025
- Dividend Yield
- SABS N/A
- NXTC N/A
- EPS Growth
- SABS N/A
- NXTC N/A
- EPS
- SABS N/A
- NXTC N/A
- Revenue
- SABS $377,835.00
- NXTC N/A
- Revenue This Year
- SABS N/A
- NXTC N/A
- Revenue Next Year
- SABS N/A
- NXTC N/A
- P/E Ratio
- SABS N/A
- NXTC N/A
- Revenue Growth
- SABS N/A
- NXTC N/A
- 52 Week Low
- SABS $1.00
- NXTC $2.69
- 52 Week High
- SABS $5.01
- NXTC $21.48
- Technical
- Relative Strength Index (RSI)
- SABS 75.33
- NXTC 47.80
- Support Level
- SABS $2.31
- NXTC $4.60
- Resistance Level
- SABS $2.98
- NXTC $5.37
- Average True Range (ATR)
- SABS 0.24
- NXTC 0.50
- MACD
- SABS 0.09
- NXTC -0.01
- Stochastic Oscillator
- SABS 89.31
- NXTC 47.86
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.